TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: While TP53 mutations in both CML and CLL confer poor prognosis, their implications differ; in CML, they mark transformation to a more advanced disease stage, whereas in CLL, they drive resistance to standard therapies and necessitate targeted treatment approaches [245].